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Abstract
Background: Experimental studies have shown an acti-
vation of the angiotensin-converting enzyme (ACE) sys-
tem as a response to endothelial injury. Recent publica-
tions have elucidated the hypothesis that the ACE gene
polymorphism may influence the level of late luminal
loss after coronary stent implantation. It is still unclear
whether the polymorphism of the angiotensin gene is a
major predictor of the extent of neointimal hyperplasia.
In this multicenter study, we therefore tested the rela-
tionship between the ACE gene polymorphism and the
restenosis rate after coronary stent implantation. Meth-
ods: As a substudy of the optimization with intracoronary
ultrasound (ICUS) to reduce stent restenosis (OPTICUS)
study, we analyzed ACE serum levels and the ACE gene
polymorphism in 154 patients at 9 different centers. All
patients underwent elective coronary stent implantation
in a stenosis of a major coronary vessel. Balloon infla-
tions were repeated until a satisfactory result was
achieved in on-line quantitative coronary angiography or
ICUS fulfilling the OPTICUS study criteria. After follow-
up of 6 months, all patients underwent reangiography
under identical projections as the baseline procedure. A
blinded quantitative analysis of the initial procedure as
well as the follow-up examinations were performed by
an independent core laboratory. ACE gene polymor-
phism and ACE serum activity were measured at the 6-
month follow-up in a double-blinded setting. Results:
With respect to the ACE gene polymorphism, there were
three subgroups: DD genotype (48 patients), ID (83 pa-
tients) and II (23 patients). The subgroups did not differ in
regard to age, gender, extent of coronary artery disease,
stenosis length, initial degree of stenosis or degree of
stenosis after stent implantation. In all, 39 patients
(25.3%) had significant restenosis: 12 DD patients
(25.0%), 18 ID patients (21.7%) and 9 II patients (39.1%)
(odds ratio 2.164, 95% confidence interval 0.853–5.493).
We obtained the following results for ACE serum levels:
0.53 Ìmol/l/s in the DD subgroup, 0.29 Ìmol/l/s in the ID
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subgroup and 0.09 Ìmol/l/s in the II subgroup (p ! 0.001).
Multivariate logistic regression analysis of the influence
of ACE gene polymorphism on the restenosis rate after
coronary stent implantation adjusted for lesion length
(112 mm), ACE inhibitor or hydroxymethylglutaryl coen-
zyme A reductase (CSE) inhibitor treatment, age, male
gender, diabetes mellitus, hypertension, high cholester-
ol, family history, smoking and three-vessel disease did
not uncover any statistic significance. Conclusions: In
contrast to other study groups, we were unable to dis-
close that the DD polymorphism of the ACE gene was
associated with a higher rate of restenosis after coronary
stent implantation in this multicenter study. In addition,
patients with higher ACE serum levels did not show a
higher restenosis rate in this trial. We conclude that the
pathogenesis of restenosis is a multifactorial process
involving various genetic and nongenetic factors.
Copyright © 2002 S. Karger AG, Basel
Introduction
After 20 years of coronary angioplasty, the develop-
ment of restenosis is still an unsolved problem [1]. Stent
implantation reduces the restenosis rate compared to con-
ventional balloon angioplasty [2, 3]. However, even after
optimized stent deployment under the guidance of intra-
vascular ultrasound, relevant luminal loss still occurs [4].
Recently, the influence of the local angiotensin system
and medical inhibition of the angiotensin-converting en-
zyme (ACE) on the prognosis after percutaneous translu-
minal coronary angioplasty has become a major object of
research [5]. Stent implantation inhibits the process of
remodeling after coronary angioplasty [6]. However, the
enhanced neointimal hyperplasia after stenting remains a
challenge in clinical research. Experimental studies have
shown a relationship between serum angiotensin levels
and the development of arteriosclerosis [7]. Animal ex-
periments have demonstrated the ability of ACE inhibi-
tors to reduce neointimal thickening after endothelial
injury [8].
A genetic polymorphism in the ACE gene determines
the serum ACE concentration [9]. It has also been suggest-
ed that this insertion/deletion (I/D) polymorphism of a
250-base-pair-long DNA sequence determines the reste-
nosis rate after coronary stent implantation [10]. Further-
more, serum plasma activity of ACE has been thought to
play a major role in the development of restenosis after
coronary stent implantation [11].
However, these recent single-center studies were per-
formed in selected patients. Blinded analysis of a multi-
center study is still missing; therefore, the present investi-
gation was undertaken.
Patients and Methods
The present study was designed as a substudy of a large multicen-
ter angioplasty trial. It was the aim of the substudy to analyze the role
of the ACE polymorphism in restenosis rates in a multicenter set-
ting.
Patient Selection
The present study is a substudy of the optimization with intracor-
onary ultrasound (ICUS) to reduce stent restenosis (OPTICUS)
study, in which the influence of ICUS on the long-term results after
coronary stent implantation was investigated. The population con-
sisted of 550 patients altogether. On the basis of the Multi-Center
Ultrasound Stenting in Coronaries (MUSIC) study, the patients were
prospectively randomized for optimal stent implantation under the
guidance of intravascular ultrasound or quantitative coronary angi-
ography [4]. The details of the OPTICUS study are described else-
where [12].
Patient recruitment for the substudy was on a volunteer basis (in-
clusion rate 28%). Nine European centers participated in the ACE
substudy. Between January 1996 and January 1998, 154 patients
with elective coronary stent implantation were included. All patients
fulfilled the inclusion criteria of the OPTICUS study; i.e. patients
who were scheduled to undergo elective coronary angioplasty of one
lesion were eligible. Patients with stable angina [Canadian Cardio-
vascular Society (CCS) class I–III], unstable angina (Braunwald 1A–
2C) or silent ischemia were included. The lesion length had to be
^25 mm and the vessel diameter had to be 62.5 mm (by visual
estimation). We excluded patients with left main disease (650%
lumen narrowing), angiographic evidence of thrombus, bifurcation
lesion, significant side branch involvement (62.5 mm in diameter),
Q-wave infarction or akinesia in the myocardium supplied by the
vessel of interest, lesions of bypass vessels, lesions in a bifurcation
and severe accompanying disease. All patients had to give written
informed consent. The study was performed with the approval of
each local ethical committee.
Study Protocol
Coronary angiography was performed in the standard manner by
femoral approach with 6- to 8-Fr guiding catheters. After intracoro-
nary injection of 0.2 mg of nitroglycerin, quantitative coronary angi-
ography of the target lesion was performed. After administration of
10,000 IU of heparin, the stenosis was predilated. Subsequently, a
Palmaz-Schatz stent (Power GripTM or CrownTM, Johnson & John-
son, Warren, N.J., USA) or a NIRTM stent (Boston Scientific Corp.,
Natick, Mass., USA) was implanted. Balloon inflations with a pres-
sure of 614 atm were performed until the study criteria of optimal
stent expansion were achieved. According to a randomization
scheme, in half of the patients, an additional examination of the tar-
get vessel was performed by ICUS. Further details of the OPTICUS
criteria are described elsewhere [12].
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ICUS criteria of optimal stent expansion were: complete apposi-
tion of the stent over its entire length against the vessel wall, an in-
stent luminal area (LA) of the proximal stent entrance 690% of the
proximal LA, an in-stent minimal LA of 690% of the average refer-
ence LA [(proximal LA + distal LA)/2] or 6100% of the reference
segment with the lowest LA. In vessels with an in-stent minimal LA
of 69.0 mm2, the cutoff value of the latest criterion was lowered by
10%.
The medication appropriate to each individual consisted of
nitrates, ß-blockers, ACE inhibitors and lipid-lowering drugs. All
patients received aspirin as standard medication and ticlopidine
250 mg b.i.d. for 2 weeks.
Follow-Up
The follow-up period was 6 months. All patients underwent rean-
giography. The second procedure was performed under identical
conditions as the baseline procedure with respect to the projections
of fluoroscopy and intracoronary injection of nitroglycerin. Clinical
events such as death, acute myocardial infarction, repercutaneous
transluminal coronary angioplasty, bypass surgery or intracranial
hemorrhage, as well as current medication, especially ACE inhibi-
tors, for each patient were documented. Blood samples were taken
for analysis of the ACE gene polymorphism and the serum ACE
activity.
The late event rate was obtained by a final interview after 12
months.
Quantitative Coronary Angiography
The method of the quantitative coronary angiography analysis
was described previously [13]. Offline quantitative coronary angiog-
raphy was performed by an independent center in a blinded fashion.
The results of the baseline procedure and the follow-up examination
were analyzed in the same way. Automatic contour detection was
performed with a geometric edge differentiation technique as de-
scribed previously [14]. All values are mean values of the analysis of
at least two orthogonal planes. The degree of stenosis was calculated
as the relation between the minimal luminal diameter and the aver-
age luminal diameter of the proximal and distal reference segment.
Blood Sample Analysis
Six months after stent implantation, all patients underwent rean-
giography. At that time, we took blood samples for analysis of the
ACE I/D polymorphism and analysis of serum ACE activity.
All patients were questioned with respect to ACE inhibitor treat-
ment. ACE gene polymorphism and ACE serum activity were ana-
lyzed in a double-blinded setting by an independent laboratory.
Genome DNA was extracted from 200 Ìl of whole blood with a
standard kit (QUIAmp, Quiagen). The ACE gene I/D polymorphism
was determined according to the method of Rigat et al. [9]. Plasma
ACE activity was measured through quantitative kinetic determina-
tion by photometry at 340 nm after a sufficient amount of N-(3-[2-
Furyl]acryloyl)-Phe-Gly-Gly (FAPGG) substrate (Sigma Diagnos-
tics) was added to the serum sample (150–200 Ìl).
To avoid genotyping bias, we performed a second reassessment of
the DNA samples of all DD patients using a primer pair that recog-
nizes an insertion-specific sequence [15].
Statistical Analysis
All values are expressed as mean B standard deviation (SD).
p values were calculated using the paired Student’s t test for statisti-
cal analysis of continuous variables within a group. Associations
between groups were tested for using the two-tailed unpaired t test
and Kruskal-Wallis test.
A p value !0.05 was considered statistically significant. Multi-
variate logistic regression analysis with a confidence interval (CI) of
95% was performed using SPSS 10.0 (SPSS Inc.).
Results
Detailed results of the OPTICUS study are published
elsewhere [12]. There was no difference between angio-
graphic guidance and ICUS guidance of coronary stent
implantation with respect to the restenosis rate and fol-
low-up results. The outcome of the patients was not
influenced by the type of stent.
Baseline Results
Between January 1996 and February 1997, 154 pa-
tients from 9 European centers were enrolled in the
OPTICUS ACE substudy. All patients met the inclusion
criteria. It was possible to implant a stent in all patients
with an initially optimal result. The early gain after stent
implantation was 2.0 B 0.36 mm. We did not observe any
acute myocardial infarction or other severe clinical event
in the 154 patients of the substudy population during the
baseline procedure. Demographic baseline characteristics
are shown in table 1.
Follow-Up Results
After an average of 6 months (range 5–8 months), all
patients underwent reangiography with the same projec-
tions as at baseline. In 39 patients (25.3%), we observed a
significant late luminal loss of 650%. As shown in fig-
ure 1, the restenosis rate among the II homozygotes
showed a tendency to be higher compared to that in ID
and DD individuals. However, logistic regression analysis
of II versus DD/DI showed an odds ratio of 2.164 (95%
CI 0.853–5.493), which cannot be considered statistically
significant in this study population. At baseline, all pa-
tients were comparable according to angiographic find-
ings (table 2). Figure 2 shows the cumulative distribution
curves of the three subgroups according to the ACE gene
polymorphism.
At the 12-month follow-up, 24 patients (15.6%) re-
ported a cardiac event which had occurred between 6 and
12 months after stent implantation. Six patients (12.5%)
in the DD group, 14 patients (16.9%) in the ID group and
4 patients (17.4%) in the II group had suffered an event
(no statistically significant difference).
Number
Extent of CAD
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Table 1. Baseline characteristics
All patients DD DI II
154 48 (31%) 83 (54%) 23 (15%)
Age, years 61B9.9 60B9.5 62B10.0 60B9.9
Males 119 (77.3%) 40 (83.3%) 59 (71.1%) 20 (87.0%)
Diabetes 33 (21.4%) 11 (22.9%) 19 (22.9%) 3 (13.0%)
Hypertension 81 (52.6%) 27 (56.3%) 41 (49.4%) 13 (56.5%)
Smokers 40 (26.0%) 13 (27.1%) 21 (25.3%) 6 (26.1%)
High cholesterol 105 (68.2%) 35 (72.9%) 53 (63.9%) 17 (73.9%)
Family history 55 (35.7%) 16 (33.3%) 33 (39.8%) 6 (26.1%)
CSE inhibitor treatment 57 (37.0%) 17 (35.4%) 31 (37.3%) 9 (39.1%)
ACE inhibitor treatment 51 (33.1%) 14 (29.2%) 25 (30.1%) 12 (52.2%)
Subgroups were formed according to the ACE gene polymorphism (DD, DI, II). Values
are mean B SD percentage of subgroup.
Table 2. Angiographic findings
All patients DD DI II
One vessel
Two vessels
Three vessels
83 (53.9%)
47 (30.5%)
24 (15.6%)
25 (52.1%)
15 (31.2%)
8 (16.7%)
45 (54.2%)
26 (31.3%)
12 (14.5%)
13 (56.5%)
6 (26.1%)
4 (17.4%)
Vessel of interest
LAD
RCX
RCA
86 (55.8%)
29 (18.8%)
39 (25.3%)
27 (56.3%)
10 (20.8%)
11 (22.9%)
48 (57.8%)
13 (15.7%)
22 (26.5%)
11 (47.8%)
6 (26.1%)
6 (26.1%)
Length of stenosis, mm 11.3B5.62 10.4B4.50 11.9B6.25 11.0B5.08
AHA/ACC Classification
A
B1
B2
C1
C2
5 (3.2%)
32 (20.8%)
88 (57.1%)
27 (17.5%)
2 (1.3%)
0 (0%)
13 (27.1%)
27 (56.3%)
8 (16.7%)
0 (0%)
3 (3.6%)
12 (14.5%)
53 (63.9%)
13 (15.7%)
2 (2.4%)
2 (8.7%)
7 (30.4%)
8 (34.8%)
6 (26.1%)
0 (0%)
Reference diameter, mm
At baseline
After stent implantation
At follow-up
3.0B0.53
3.1B0.47
3.0B0.49
3.1B0.53
3.1B0.49
3.0B0.45
3.0B0.54
3.1B0.48
3.0B0.51
3.0B0.46
3.1B0.39
3.0B0.50
MLD at baseline, mm 1.0B0.35 1.0B0.39 1.0B0.34 1.0B0.31
MLD after stent, mm 3.0B0.46 3.0B0.48 3.0B0.47 3.0B0.36
MLD at follow-up, mm 1.9B0.73 2.0B0.77 2.0B0.65 1.7B0.86
Loss index, % 55B34.0 52B33.8 53B29.3 63B35.8
(late loss/early gain)
Values are mean B SD. CAD = Coronary artery disease; LAD = left anterior descending;
RCX = left circumflex coronary artery; RCA = right coronary artery; AHA = American Heart
Association; ACC = American College of Cardiology; MLD = minimal luminal diameter;
n.s. = not significant by t test.
n.s. n.s.
n.s.
n.s. n.s.
n.s.
n.s. n.s.
n.s.
n.s. n.s.n.s.
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Fig. 1. Degree of stenosis before and after
stent implantation and at follow-up in the
three subgroups according to the ACE I/D
genotypes (values are presented as mean B
SD).
Fig. 2. Cumulative distribution curves of
minimal luminal diameter as a function of
the ACE I/D genotype. a Before angioplasty
(baseline) and after stent implantation (post
stent). b After 6 months of follow-up (6M-
FU).
No ACE inhibitor
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Table 3. Restenosis rate (650% diameter stenosis during follow-up) and serum ACE activity in patients with and
without ACE inhibitor treatment
ACE activity, Ìmol/l/s
all patients DD DI II
All patients
Patients with restenosis
0.36B0.503
0.30B0.325
0.55B0.421
0.50B0.338
0.30B0.558
0.23B0.305
0.10B0.067
0.13B0.095
(n = 27; 26.2%) (n = 9; 26.5%) (n = 13; 22.4%) (n = 5; 45.5%)
On ACE inhibitor
All patients
Patients with restenosis
0.30B0.402
0.33B0.427
0.49B0.544
0.69B0.447
0.26B0.287
0.11B0.025
0.07B0.0072
0.03B0.005
(n = 12; 23.3%) (n = 3; 21.4%) (n = 5; 20.0%) (n = 4; 33.3%)
Patients with and without ACE inhibitor
All patients
Patients with restenosis
0.34B0.477
0.31B0.356
0.53B0.462
0.56B0.388
0.29B0.501
0.21B0.283
0.09B0.070
0.09B0.091
(n = 39; 25.3%) (n = 12; 25.0%) (n = 18; 21.7%) (n = 9; 39.1%)
Values are mean B SD.
Gene Polymorphism and ACE Serum Activity
The serum ACE activity was 6 times higher in DD
patients than in II homozygous individuals (0.53 vs.
0.09 Ìmol/l/s). Heterozygous patients (ID) had an average
ACE activity of 0.29 B 0.501 Ìmol/l/s. The ACE activi-
ties of all patients are depicted in table 3, differentiating
between those patients who were under medication with
ACE inhibitors and those without ACE activity-influenc-
ing therapy.
Statistical Analysis of Risk Factors
Multivariate logistic regression analysis did not show
any statistical significance for the ACE gene polymor-
phism as a risk factor of restenosis after stent implanta-
tion, including lesion length (112 mm), ACE inhibitor or
CSE inhibitor treatment, age, male gender, diabetes, hy-
pertension, high cholesterol, family history, smoking and
three-vessel disease. The odds for DD patients and DI
patients were 0.536 (95% CI 0.119–2.411) and 0.486
(95% CI 0.121–1.918), respectively.
The odds ratio for II patients compared to DD/DI
patients was 2.164, with a 95% CI of 0.853–5.493.
Furthermore, the relative risk of restenosis did not
show any correlation with the degree of restenosis nor the
restenosis rate (odds ratio 1.002, 95% CI 0.990–1.014).
Discussion
In this prospective multicenter study, we tested the
hypothesis that the ACE gene DD/ID polymorphism is a
predictor of restenosis after coronary stent implantation.
In 154 patients at 9 different centers, we were unable to
discover that those with the DD/ID polymorphism of the
ACE gene had a higher extent of restenosis after coronary
stent implantation compared to those with the II poly-
morphism. In addition, the ACE serum levels did not
show any significant correlation with the restenosis rate.
ACE Gene Polymorphism
Recently published single-center studies have impli-
cated an interaction of this polymorphism located in
intron 16 of the ACE gene with the amount of late luminal
loss after stenting in a selected group of patients [10, 11].
Several studies have shown a correlation between the
ACE gene polymorphism and the extent of arteriosclero-
sis, while other studies have disproved this relationship
[16–18]. A meta-analysis of 3,394 patients by Samani et
al. [19] revealed an odds ratio of 1.26 for myocardial
infarction among DD homozygotes compared to an ID/II
population. Our findings are also supported by a recently
published single-center study with a follow-up angiogra-
phy rate of 84% [20]. In that study, Koch et al. [20] did
not find any association between the polymorphism of the
ACE gene and the restenosis rate after coronary stent
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placement. A retrospective analysis of the Framingham
Heart Study showed an association between the ACE gene
polymorphism and one major risk factor of coronary
artery disease only in men but not in women [21]. DD
homozygotes probably have an increased risk of arterio-
sclerosis and myocardial infarction if they show major
risk factors like hypertension, hypercholesterolemia or
diabetes mellitus [17, 22]. Individuals with D alleles also
show a higher body fat mass compared to II homozygotes,
which may also influence the cardiovascular risk profile
[23]. However, most studies showing any correlation be-
tween ACE gene polymorphism and arteriosclerosis in-
vestigated a multifactorial process. The ACE system only
plays a minor role compared to other factors of atherogen-
esis. The risk analysis of stent restenosis is even more
complex, since major risk factors of coronary artery dis-
ease are not associated with a significantly elevated reste-
nosis rate.
ACE Serum Activity
A correlation between the ACE serum activity and the
restenosis rate after stent implantation has been brought
up in a recently published study [11]. Animal experiments
have shown that a reduction of ACE activity by medical
treatment can reduce the amount of neointima formation
in arteries of rats [5]. However, the dosage of ACE inhibi-
tor used in the animal experiments was much higher than
dosages endured by humans [7]. Lower doses of ACE
inhibitor did not result in a reduction of the restenosis
rate after balloon angioplasty [24, 25].
In our study population, there was no significant corre-
lation between ACE activity and the restenosis rate after
stent implantation. Although the ACE activity was lower
among patients who received ACE inhibitors, the resteno-
sis rate did not differ significantly compared to those
without ACE inhibitor medication.
Conclusion
In this multicenter study, we disproved the hypothesis
that the DD/ID polymorphism of the ACE gene is of
importance in the development of restenosis after coro-
nary stent implantation.
In addition, the ACE serum levels did not correlate
with the restenosis rate. In vitro experiments as well as
further studies with larger number of patients may give
more insights into the multifactorial process of vascular
remodeling and restenosis after coronary stent implanta-
tion.
We conclude that the pathogenesis of stent restenosis is
a multifactorial process influenced by various genetic and
nongenetic factors, but is not determined by the ACE gene
polymorphism.
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